Xencor, Inc.
XNCR
NASDAQ·Healthcare·Biotechnology·Mkt cap $2.0B
$26.61
▼ -0.04%
P/E
-12.26
Mkt Cap
$2.0B
52-Wk Range
$8.19–$30.61
52-Week Range
$8.19 - $30.61
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 216.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Proprietary XmAb antibody engineering platform enabling enhanced therapeutic efficacy and reduced toxicity
- Diverse clinical pipeline with multiple candidates in Phase I/II trials reducing development risk
- Strategic partnerships with Novartis, Bristol Myers Squibb, and Vir Biotechnology providing capital and expertise
Bear Case
1 risk
- Average volatility.
Growth
Strong growth ahead
Advancement of Phase II candidates (Vudalimab, Tidutamab, VIR-3434) toward potential regulatory approvals
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+133.2% over 3m
Quality
Strong
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying XNCR right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 5, 2026
Reported EPS of -$0.29 vs -$0.80 consensus (+63.8% surprise). Revenue of $51.2M vs $18.9M expected (+171.2%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+63.8%
Revenue trend · last 8Q
—
+37%
+105%
+157%
+18%
-60%
-86%
-100%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$17.8M
$70.0M
$32.7M
$43.6M
$21.0M
$28.2M
$4.5M
$0
Margins · last 8Q
Gross
—
Operating
—
Profit
—
Wall Street consensus
4 analysts · 75% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
75%
Hold
25%
Sell
0%
Median Price Target
—
Latest: Raymond James · Sep 1, 2026
vs Industry
How XNCR stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related